| 0.9036 0.029 (3.3%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.38 | 1-year : | 6.66 |
| Resists | First : | 3.75 | Second : | 5.7 |
| Pivot price | 1.1  |
|||
| Supports | First : | 0.58 | Second : | 0.49 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 2.16 |
| MA(100) : | 6.37 |
MA(250) : | 9.41 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 6.1 |
D(3) : | 5.8 |
| RSI | RSI(14): 19.9 |
|||
| 52-week | High : | 18.54 | Low : | 0.58 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACRS ] has closed above bottom band by 44.8%. Bollinger Bands are 52.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.92 | 0.92 - 0.92 |
| Low: | 0.83 - 0.83 | 0.83 - 0.84 |
| Close: | 0.87 - 0.87 | 0.87 - 0.88 |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Tue, 21 Nov 2023
Do Traders Think Aclaris Therapeutics Inc (ACRS) Can Keep Climbing Tuesday? - InvestorsObserver
Thu, 16 Nov 2023
Is Aclaris Therapeutics Inc (ACRS) Stock Worth a Buy Thursday? - InvestorsObserver
Mon, 13 Nov 2023
5 Philadelphia-area companies make Deloitte's 2023 list of 500 ... - The Business Journals
Mon, 13 Nov 2023
Legend enters potential $1B deal with Novartis for T-cell therapies - BioWorld Online
Mon, 13 Nov 2023
Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher ... - Investing.com UK
Mon, 13 Nov 2023
US Stocks Fall; Tyson Foods Posts Upbeat Earnings - Mainz Biomed (NASDAQ:MYNZ), Aclaris Therapeutics (NAS - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 71 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 102.6 (%) |
| Shares Short | 6,580 (K) |
| Shares Short P.Month | 5,930 (K) |
| EPS | -1.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | 0 % |
| Operating Margin | -321.9 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -61 % |
| Qtrly Rev. Growth | -51.3 % |
| Gross Profit (p.s.) | -0.85 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.55 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.4 |
| Price to Sales | 2.98 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|